The $35 million deal with Mallinckrodt Pharmaceuticals requires the company to take further steps in reporting suspicious orders of its drugs.
The $35 million deal with Mallinckrodt Pharmaceuticals requires the company to take further steps in reporting suspicious orders of its drugs.